Monoclonal Antibody Against Human CEA (3519)
Product#: FNK-2AHCMC1
$260.92
Availability:
Ships in 1-2 Weeks
Monoclonal Antibody Against Human CEA (3519)
| Cat. No: | FNK-2AHCMC2 |
| Clone No: | Hyb-3519 |
| Manufacturing Process: | Hybridoma obtained by fusing mouse myeloma cells (NS-1) with BALB/c mouse spleen cells immunized with carchinoembryonic antigen (CEA) derived from human cancer tissue is proliferated in the BALB/c mouse abdominal cavity and ascites is collected. |
| Specificity: | The reactivity is CEA+, NCA- and NCAⅡ+. |
| Purification: | Ammonium sulfate precipitation. |
| Ig Class: | IgG1 |
| Form: | Saline (containing 0.1% NaN3) |
| Protein Concentration: | 0.5 mg/mL |
| Package: | 0.2 mL |
| Storage: | 2-8℃ (Below -20℃ for long term storage) |
| Shipping Condition: | Dry Ice |
| Application: | ELISA |
Antigen Characterization
- Type: Primary
- Application: ELISA (Enzyme-Linked Immunosorbent Assay), Western Blot, Immunohistochemistry
- Species: Human
- Recombinant: Yes
Human Diseases
- Colorectal Cancer: CEA is the most widely used biomarker for colorectal cancer. Elevated levels are associated with disease progression and can be used for monitoring treatment response and detecting recurrence.
- Lung Cancer: CEA is elevated in 40-50% of patients with non-small cell lung cancer and can be used as a prognostic marker.
- Breast Cancer: CEA levels are elevated in 30-50% of breast cancer patients and correlate with disease stage.
- Pancreatic Cancer: CEA is a useful marker for monitoring treatment response and detecting recurrence in pancreatic cancer patients.
Cellular Signaling Pathways
- Cell Adhesion and Migration: CEA acts as a cell-cell adhesion molecule, influencing cell-cell interactions and cell migration processes.
- Angiogenesis: CEA may play a role in promoting angiogenesis, the formation of new blood vessels, which is crucial for tumor growth and metastasis.
- Immune Modulation: CEA can modulate immune responses by interacting with immune cells and affecting their activation and function.
- Apoptosis: CEA may be involved in regulating apoptosis, or programmed cell death, which can contribute to tumor progression and metastasis.
Aliases for CEA Gene
- Carcinoembryonic Antigen
- CEA Test
- CEA Assay
- CD66e
- CEACAM5
- Meconium antigen 100
References
- “Cea (CEA31) Mouse Monoclonal Antibody.” Diagnostics, diagnostics.roche.com/global/en/products/lab/carcinoembryonic-antigen-cea31-rtd000737.html.
- H, Wu, et al. “A Photo-Cross-Linking GlcNAc Analog Enables Covalent Capture of N-Linked Glycoprotein-Binding Partners on the Cell Surface.” (MA5-14675), www.thermofisher.com/antibody/product/CEA-Antibody-clone-1106-Monoclonal/MA5-14675.
- “CEA Test: Carcinoembryonic Antigen Levels and Results.” City of Hope, City of Hope, 15 Nov. 2021, www.cancercenter.com/diagnosing-cancer/lab-tests/cea-test.
- Professional, Cleveland Clinic medical. “CEA Test (Carcinoembryonic Antigen): What It Is & Results.” Cleveland Clinic, 1 May 2024, my.clevelandclinic.org/health/diagnostics/22744-cea-test-carcinoembryonic-antigen.
- Kankanala, Vijaya L. “Carcinoembryonic Antigen.” StatPearls [Internet]., U.S. National Library of Medicine, 23 Jan. 2023, www.ncbi.nlm.nih.gov/books/NBK578172/.
- Kira H. Bramswig, Marina Poettler, Matthias Unseld, Friedrich Wrba, Pavel Uhrin, Wolfgang Zimmermann, Christoph C. Zielinski, Gerald W. Prager; Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis. Cancer Res 15 November 2013; 73 (22): 6584–6596. https://doi.org/10.1158/0008-5472.CAN-13-0123
- Bernhard B. Singer, Inka Scheffrahn, Robert Heymann, Kristmundur Sigmundsson, Robert Kammerer, Bjo?rn O?brink; Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Expression and Signaling in Human, Mouse, and Rat Leukocytes: Evidence for Replacement of the Short Cytoplasmic Domain Isoform by Glycosylphosphatidylinositol-Linked Proteins in Human Leukocytes1. J Immunol 15 May 2002; 168 (10): 5139–5146. https://doi.org/10.4049/jimmunol.168.10.5139
- Hensel, J. A., Khattar, V., Ashton, R., & Ponnazhagan, S. (2018). Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity. Molecular therapy oncolytics, 12, 41–48. https://doi.org/10.1016/j.omto.2018.12.004
